Alicia Havens
Optometrist · New Port Richey, FLNPI 1437566155
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 16 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by AbbVie at 28.3% of the total. 2025 is the largest year on record at $287, more than ten times the $18 reported in 2020. That places this record below the midpoint for optometrist clinicians in FL, where the typical reported total is $857.
Across 16 payments — averaging $23.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$106
- Biotissue Holdings Inc.$82
- Bausch & Lomb Americas Inc.$46
- Alcon$36
- Glaukos Corporation$33
- Merz Pharmaceuticals, LLC$29
- plus $43 from 2 others
What the payments were for
- Food & beverage$374100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 4 | $106 |
| Biotissue Holdings Inc. | 4 | $82 |
| Bausch & Lomb Americas Inc. | 2 | $46 |
| Alcon | 2 | $36 |
| Glaukos Corporation | 1 | $33 |
| Merz Pharmaceuticals, LLC | 1 | $29 |
| Sun Pharmaceutical Industries Inc. | 1 | $24 |
| Sight Sciences, Inc. | 1 | $19 |
How this compares
$374 in reported general payments places this provider in the 30th percentile of 3,166 optometrist providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 43 | $1,657 |
| Latanoprost | 117 | $1,345 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 56 | $651 |
| Timolol Maleate | 40 | $487 |
| Dorzolamide Hcl | 15 | $323 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 19 | $318 |
| ErythromycinErythromycin Base | 16 | $195 |
| Brimonidine Tartrate | 19 | $153 |
| Ciprofloxacin Hcl | 11 | $124 |
| Cephalexin | 11 | $85 |
Paid to pharmacies, not to this prescriber.
Other optometrist in New Port Richey
- James HoffmanOrange Park$795K
- April JasperWest Palm Beach$553K
- Nora CothranLargo$505K
- Michael SluskyNorth Port$384K
- Katie SpearDefuniak Springs$361K
- Karen HoffmanOrange Park$282K
- Ashley RothMiami Beach$261K
- Jessica SteenDavie$256K
- Mark DunbarMiami$236K
- Robert DavisPembroke Pines$217K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.